image image image

“SEE-DRUG ” is a FP7 - RESEARH POTENTIAL project that aims to the upgrade the Structural Biology capacities of UPAT and to the Establishment of a Center of Excellence for Structure-Based Drug Target chracterization efforts in South-Eastern EU region.
Read the Full Story

“SEE-STRUCT” is structure-oriented module of SEE-DRUG project and aims to the structural elucidation of proteins, enzymes and other interesting drug-targets. The tools offered for these efforts are a state-of-the-art high field NMR instrument of 700 MHz equipped with a highly sensitive probe and crystallization robot.
Read the Full Story

“SEE-PROT” & “SEE-PHARM” are the protein production and the preclinical evaluation of molecules, modules of SEE-DRUG project. The tools offered for these efforts are protein production and characterization facilities an upgraded confocal microscope, an intravital microscope and myographs.
Read the Full Story

NMR
700MHz
High sensetivity probe
Studies in solution
Conformation/Dynamics
3D Structure determination, mobility, protein-protein interaction, protein-drug interactions
Confocal
In-cell imaging
Leica Microscope
Tandem Scanner
Additional laser
Sub-cellular ablation in live cells, protein-complexes, protein drug interactions in vivo
Robot
Crystal growth
Automation
Crystalization trials
Fast & efficient
Crystal growth optimization, screen of protein targes in paraller with NRM Spectroscopy
Microscopes
Myographs
intravital Microscope
In vivo
Ex vivo
Drug screening for anti-inflammatory compounds, evaluation of vasoactive compounds

Stuctural Biology
NMR & Xray
2H/13C/15N labeling
Selective labeling
Crystallization
Conformation dynamics, Modeling Structure determination, 3D solutions & crystal models, Bioinformatics
Molecular Biology
Biochemistry
Drug-targets
Biochemical pathways
Protein production
High-yield protein expression, labeling & isolation for structural studies, protein biochemistry
Imaging
In-cell studies
Functional imaging
Light Microscopy
FRET measurements
Studies of biomolecular functions through Advanced Light Microscopy, Sub-cellular ablations
Pharmacology
Inflammation
Vascular Biology
Cell-based assays
Signaling pathways
Monitoring cell processes (migration. proliferation, apoptosis), in vivo & ex vivo assays

Expertise Exchange
Twinnings
Knowledge transfer
Best practices
New applications
Exchange of researchers between UPAT and partnering organizations - EU Centers of excellence
Events
Workshops
Structural Biology
Biochemistry
Imaging
Workshops and scientific meetings will be organized at UPAT, Advanced training course in NMR
Dissemination
Conferences
Biomolecular NMR
Life Sciences
Analysis
Invited talks, Meeting participation & Poster presentations by SEE-DRUG members
Brokerage Events
Info-days
Meet the expers
Links with industry
Regional Authorities
Colloquia with invited speakers from academia or industry and private sector stakeholders

SEE-PROT & SEE-PHARM


“SEE-PROT” & “SEE-PHARM” are the protein production and the preclinical evaluation of molecules, modules of SEE-DRUG project. The tools offered for these efforts are protein production and characterization facilities an upgraded confocal microscope, an intravital microscope and myographs.

SEE-PROT: Production of protein & peptides and screening/optimization of polypeptide samples, for structural and functional studies either by NMR or by X-ray and other biophysical techniques. This module will allow UPAT’s researchers and researchers from other regional (Greek, South-Eastern EU or other) institutes, to gain experience, to collaborate with SEE-DRUG experts and finally to achieve the identification, cloning, production and characterization of new protein drug-targets that will be forwarded for structural characterization, and for the study of their interaction with other protein/peptide partners and drug screening. The availability of proteins suitable for structural analysis constitutes a major bottleneck in structural biology and structure-based drug design methodologies. Although over-expression in bacteria is a well-established process and the collaborating groups of the SEE-DRUG consortium have a long-term experience in the efficient production of peptide and protein samples for structural and functional studies, there are certain types of proteins, involved in biochemical pathways of tumour growth and/or suppression, cardiovascular and neurodegenerative diseases that are the main research targets of the team, and which may need the incorporation of eukaryotic or mammalian expression systems. Additionally, a state-of-the-art NMR methodology relies on the investigation of proteins, RNA and DNA that are uniformly or selectively enriched with NMR-active nuclei, such as 13C and 15N, while sometimes requires combination of the enrichment to the above nuclei with 1H substitution by 2H nuclei.


SEE-PHARM: Disease-modelling cell-based assays including live cell imaging techniques, complemented by ex vivo and in vivo screening, to test protein-protein/peptide and protein-drug lead interactions, evaluate efficacy of candidate molecules, determine new biomolecular interactions and study the effects of the leads on basic cellular pathways. SEE-PHARM’s role will therefore be to use all its available tools to test bio-molecules developed on NMR structure-based information and provide valuable feedback regarding their optimization. The upgrading of the existing Confocal Microscopy Facility, will comprise, according to our knowledge, a unique facility in Greece for its capacities, properties and applications. Additionally, the UPAT groups of Molecular Pharmacology has adequate state-of-the-art instrumentation to evaluate a broad range of processes in vitro (e.g. protein and mRNA analysis, ELISA, luciferase and fluorescence plate readers etc), being able to functionally evaluate in vivo or ex vivo some critical processes in cardiovascular and inflammatory diseases. The Intravital microscope and the Myographs: a) will significantly upgrade the groups’ ability to move lead compounds to a more significant level and b) will be perfectly complementary to the existing infrastructure. The ability to perform this testing can support the application and concur to the development of more solid intellectual property, eliminate a compound as ineffective or indicate pharmacokinetic and metabolism-related properties that can be improved and optimized. For this reason we request to add the following two setups that allow us to go a step further in our drug candidate characterization-oriented effort, which will also considerably enhanced by the information gained by NMR and Xray structural studies.

Upcoming Events

Hot off the Press

porn /div> The NMR Structure of ARKADIA RING Domain (Proteins 2012, 50, 1484-89)

H2S and NO in angiogenesis & vasodilatation (PNAS 2012 in the press)

Site Statistics

mod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_counter
mod_vvisit_counterToday53
mod_vvisit_counterYesterday227
mod_vvisit_counterThis week571
mod_vvisit_counterLast week361
mod_vvisit_counterThis month1139
mod_vvisit_counterLast month2072
mod_vvisit_counterAll days188090

We have: 10 guests online
Your IP: 54.221.136.62
 , 
Today: Dec 14, 2017
University of Patras General Info, Services, Research Committee, etc.

FP7 Research & Innovation – Participants Portal – Calls for applications

International Meetings & Conferences

Journal Club

  • 01 Jan 2012 Starting data of SEE-DRUG project

  • 23 Feb 2012 Kick-off meeting

  • 23 Apr2012 External Advisory Board meeting

  • 29 Apr 2013 700MHz NMR installed